Mymetics and Anergis announce successful pre-clinical proof-of-concept study for birch pollen allergy

Mymetics and Anergis announce successful pre-clinical proof-of-concept study for birch pollen allergy

Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the pre-clinical proof-of-concept study for allergies, with their partner Anergis SA, has met the success criteria. The mice proof-of-concept immunogenicity study evaluated the effects of the Bet v 1 COPs (Anergis’ proprietary birch pollen allergy peptides) using the five subcutaneous injection schedule used in former AllerT clinical trials.

 

Leave a reply